Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Saad Hanif Abbasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Pharmacoepidemiology, Anticoagulants, Practice Patterns, Physicians', Ischemic Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danmarks Frie Forskningsfond.
Abstract (Originalsprache)
The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity). Additionally, the type of prescriber may correlate with other factors such as treatment adherence, surveillance or coding practices. Although information on the type of prescriber is often available in healthcare registries, it is very rarely employed to control for confounding in pharmacoepidemiological analyses. Here, we argue the potential value in adjusting for the prescriber type in pharmacoepidemiological studies. In an applied example, we conducted a cohort study using Danish healthcare registers of the risk of ischemic stroke associated with the use of direct oral anticoagulants (DOACs) compared to warfarin. We found a hazard ratio (HR) of 0.95 (95% CI: 0.90–1.01) for DOACs versus warfarin when adjusting only for age and sex. Further adjustment for prescriber type showed an effect of similar magnitude (HR 0.92; 95% CI: 0.87–0.98). However, interaction testing and stratified analyses confirmed prescriber type as an effect modifier. Future studies are needed to clarify the role of adjusting for prescriber type across other use cases and healthcare settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Saad Hanif Abbasi, Jesper Hallas, Anton Pottegård
Förderung
- Danmarks Frie Forskningsfond
Zitieren
APA
Abbasi, S. H., Hallas, J., Jensen, P. B., Al-Jasim, H., & Pottegård, A. (2025). Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70126
Vancouver
Abbasi SH, Hallas J, Jensen PB, Al-Jasim H, Pottegård A. Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70126
BibTeX
@article{Abbasi2025,
author = {Abbasi, Saad Hanif and Hallas, Jesper and Jensen, Peter Bjødstrup and Al-Jasim, Hassan and Pottegård, Anton},
title = {Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70126}
}
EUVIMED